Elvina Almuradova: Chemotherapy-induced neuropathy is still one of the biggest problems reducing patients’ QOL
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on LinkedIn about a paper by Ryan D’Souza et al. published in BMJ Journals:
“Chemotherapy-induced neuropathy is still one of the biggest problems reducing patients’ quality of life!
A global analysis found that approximately 41% of cancer patients undergoing chemotherapy develop chronic painful neuropathy. The study pooled data from 77 studies across 28 countries, including nearly 11,000 patients.
Key Findings:
- Platinum-based agents (40.5%) and taxanes (38%) were associated with the highest neuropathy rates.
- FOLFOX had the lowest neuropathy prevalence (16.5%).
- Lung cancer patients had the highest prevalence (62%), while ovarian cancer (31.5%) and lymphoma (36%) had the lowest.
- Asian studies reported the highest neuropathy prevalence (46.5%), while European studies showed the lowest.
The researchers emphasized the urgent need for tailored pain management strategies and further research to understand regional and treatment-related disparities.”
Authors: Ryan D’Souza, Chandan Saini, Nasir Hussain, Saba Javed, Larry Prokop, and Yeng Her.
More posts featuring Elvina Almuradova.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023